Group 1 - Recently, Zhiran Medical, a leading company in invasive brain-computer interfaces, announced the completion of a 300 million RMB A+ round financing [1] - This is the second round of financing completed by Zhiran Medical within six months, indicating strong market recognition of its technological capabilities and development potential in the invasive brain-computer interface sector [3] - The funds raised will primarily be used to advance large-scale clinical trials and iterate high-throughput flexible brain-computer interface products, accelerating the clinical application of this technology [3] Group 2 - The global brain-computer interface industry is entering a critical window for technological differentiation and clinical transformation, with invasive, semi-invasive, and non-invasive technologies showing a competitive landscape [5] - The invasive route, with its advantages in high precision, real-time data collection, and high data acquisition volume, is becoming a core breakthrough in serious medical applications and future human-computer interaction [5] - Zhiran Medical, established in 2022, focuses on developing a new generation of invasive flexible brain-computer interface platforms for precise diagnosis and treatment of neurological diseases [5][6] Group 3 - Zhiran Medical has completed a systematic layout of the invasive brain-computer interface industry chain, establishing a complete industrial closed loop from core technology research and development to large-scale production [8] - The company has made significant breakthroughs in key technologies, including flexible electrodes, neural chips, decoding algorithms, and electrode implantation robots [8] - The recent breakthrough in high-throughput flexible electrodes addresses industry challenges related to traditional linear flexible electrodes, enhancing signal acquisition and biomechanical compliance [8][10] Group 4 - The team has successfully developed a high-throughput wireless invasive brain-computer interface system based on stretchable flexible electrodes, improving biocompatibility and signal transmission bandwidth [12] - By 2025, Zhiran Medical completed the first domestic clinical implantation of an invasive brain-computer interface product with over 100 channels, initially verifying the product's safety and effectiveness [12] - The company plans to initiate large-scale registration clinical trials for the over 100-channel invasive brain-computer interface product in 2026, accelerating its clinical deployment [12]

Core Insights - The core viewpoint of the news is that Zhiran Medical, a leading company in the invasive brain-computer interface (BCI) sector, has successfully completed a 300 million RMB A+ round of financing, indicating strong market recognition of its technological capabilities and growth potential [1][6]. Financing and Market Recognition - Zhiran Medical has completed its second round of financing within six months, attracting significant investment from various stakeholders, including Zhongke Chuangxing and existing investors [1][6]. - The funds raised will primarily be used to advance large-scale clinical trials and iterate high-throughput flexible BCI products, accelerating the technology's clinical application [1][6]. Technological Development - Zhiran Medical has firmly committed to the invasive BCI technology route, leveraging its deep technical expertise and understanding of the industry's future [1][6]. - The company has established a systematic layout in the invasive BCI industry chain, achieving breakthroughs in key technologies such as flexible electrodes, neural chips, decoding algorithms, and electrode implantation robots [3][8]. - A significant technological breakthrough has been made with the development of a stretchable high-throughput flexible electrode, which addresses industry challenges related to traditional linear flexible electrodes [3][8]. Clinical Applications and Future Plans - Zhiran Medical has successfully developed a high-throughput wireless invasive BCI system, enhancing signal stability and decoding accuracy for large-scale clinical applications [4][9]. - The company plans to initiate large-scale registration clinical trials for its over 100-channel invasive BCI products in 2026, following the successful clinical implantation of the first such product in 2025 [4][9]. - The advancements align with national strategic plans and emphasize the importance of independent innovation in cutting-edge technologies [4][9]. Future Outlook - The company aims to accelerate core technology breakthroughs and clinical transformation processes, contributing significantly to China's leadership in the invasive BCI sector [5][10].

Core Viewpoint - The article discusses the recent advancements and funding in the invasive brain-computer interface (BCI) sector, particularly focusing on the company "Zhiran Medical," which has completed a 300 million RMB A+ round of financing to enhance clinical trials and product iterations [2]. Group 1: Company Overview - Zhiran Medical has established a systematic layout in the upstream and midstream of the invasive BCI industry chain, focusing on core technology development and large-scale production [3][6]. - The company has made significant breakthroughs in key technologies, including flexible electrodes, neural chips, decoding algorithms, and electrode implantation robots, creating a complete industrial closed loop [3][6]. Group 2: Technological Advancements - Zhiran Medical's recent innovation includes a stretchable high-throughput flexible electrode that addresses issues of traditional linear electrodes, enhancing signal collection and biomechanical compliance [4][6]. - The company's neural signal acquisition chip is coin-sized and has reduced power consumption by 75% compared to traditional chips, while the deep neural network decoding algorithm allows for high-precision real-time decoding [6]. Group 3: Clinical Applications - By 2025, Zhiran Medical successfully completed the clinical implantation of the first domestic invasive BCI product with over 100 channels, validating its safety and effectiveness [6]. - The company plans to initiate large-scale clinical registration for its over 100-channel invasive BCI product in 2026, accelerating its clinical application [6]. Group 4: Industry Positioning - As a leading innovator in the domestic invasive BCI field, Zhiran Medical aligns with China's "14th Five-Year Plan" for future industry development and responds to national calls for independent innovation in cutting-edge technologies [7].